203 related articles for article (PubMed ID: 37115693)
1. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L
J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693
[TBL] [Abstract][Full Text] [Related]
2. Aspirin and immunotherapy: a Faustian bargain?
Goethe EA; Heimberger AB; Rao G
J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115694
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8
Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J
J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721
[TBL] [Abstract][Full Text] [Related]
4. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
5. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.
Nayeb-Hashemi H; Desai A; Demchev V; Bronson RT; Hornick JL; Cohen DE; Ukomadu C
Biochem Biophys Res Commun; 2015 Sep; 465(2):167-73. PubMed ID: 26225745
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
9. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
[TBL] [Abstract][Full Text] [Related]
10. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
11. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
13. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.
Hua N; Chen A; Yang C; Dong H; He X; Ru G; Tong X; Zhou F; Wang S
Mol Biol Rep; 2022 Aug; 49(8):7911-7919. PubMed ID: 35776395
[TBL] [Abstract][Full Text] [Related]
14. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Son Y; Shin NR; Kim SH; Park SC; Lee HJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
[TBL] [Abstract][Full Text] [Related]
16. A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1.
Zhang X; Zhu H; Zheng X; Jiao Y; Ning L; Zhou EM; Mu Y
Front Immunol; 2021; 12():670626. PubMed ID: 33968077
[TBL] [Abstract][Full Text] [Related]
17. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential.
Liu XH; Qi LW; Alolga RN; Liu Q
Int J Biol Sci; 2022; 18(1):292-300. PubMed ID: 34975333
[TBL] [Abstract][Full Text] [Related]
18. Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression.
Wang J; Wei W; Tang Q; Lu L; Luo Z; Li W; Lu Y; Pu J
Cancer Med; 2020 Oct; 9(19):7125-7136. PubMed ID: 32810392
[TBL] [Abstract][Full Text] [Related]
19. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
20. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion.
Zhuang Q; Dai Z; Xu X; Bai S; Zhang Y; Zheng Y; Xing X; Hu E; Wang Y; Guo W; Zhao B; Zeng Y; Liu X
Cancer Res; 2024 Feb; 84(3):405-418. PubMed ID: 37963197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
